Randomized trial · people
Ecnoglutide: HbA1c fell up to 2.39% at 20 weeks in type 2 diabetes
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In a placebo-controlled trial in people with type 2 diabetes, ecnoglutide lowered blood sugar at every dose tested over 20 weeks, and the largest drop came in the highest dose arm.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 145
- Published
- 2024
- Journal
- Nat Commun
What they tested
Does a once-weekly ecnoglutide shot lower HbA1c, a long-term average of blood sugar, in adults with type 2 diabetes after 20 weeks?
How the study was done
A randomized, double-blind, placebo-controlled phase 2 trial run at multiple centers in 145 adults with type 2 diabetes. Each person got 0.4, 0.8 or 1.2 mg of ecnoglutide or a placebo (a dummy shot) once a week for 20 weeks.

Model. Individual results vary.
What they found
By the end of treatment, HbA1c had dropped by 1.81% in the 0.4 mg arm, 1.90% in the 0.8 mg arm and 2.39% in the 1.2 mg arm, compared with 0.55% on placebo (P < 0.0001). In the 1.2 mg arm, 71.9% reached an HbA1c of 6.5% or lower, against 9.1% on placebo. In that same arm, 33.3% lost at least 5% of their body weight, against 3.0% on placebo. The researchers judged the drug safe and tolerable overall.
What it doesn’t show
With 145 people followed for 20 weeks, the trial is too small and too brief to judge lasting benefits or uncommon harms. Ecnoglutide was tested against placebo only, not against other diabetes or GLP-1 medicines.
The paper
Zhu et al. Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Commun. 2024.
The compound
More studies on Ecnoglutide
- Ecnoglutide lowered HbA1c and weight in type 2 diabetes: meta-analysisMeta-analysis · people · 2026
- Ecnoglutide: HbA1c fell up to 2.43% at 24 weeks in EECOH-1Randomized trial · people · 2026
- Ecnoglutide: HbA1c fell up to 1.91% vs 1.65% with dulaglutideRandomized trial · people · 2025
- Ecnoglutide: 13.2% weight loss at 40 weeks in the 2.4 mg armRandomized trial · people · 2025
- Ecnoglutide: well tolerated weekly for 6 weeks in a phase 1 trialRandomized trial · people · 2023
- Every study on Ecnoglutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.